Search results
Results from the WOW.Com Content Network
Benign prostatic hyperplasia ( BPH ), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. [ 1] Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. [ 1] Complications can include urinary tract infections, bladder stones, and ...
Prostatic artery embolization (PAE, or prostate artery embolisation) is a non-surgical technique for treatment of benign prostatic hypertrophy (BPH). [1]The procedure involves blocking the blood flow of small branches of the prostatic arteries using microparticles injected via a small catheter, [2] to decrease the size of the prostate gland to reduce lower urinary tract symptoms.
Tamsulosin. Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. [ 6][ 7][ 8] The evidence for benefit with a kidney stone is better when the stone is larger. [ 8] Tamsulosin is taken by mouth.
Invasive therapies. There are two invasive surgical procedures done for BPH: Transurethral resection of the prostate (TURP): In general prior to emergence of laser technologies, TURP had been considered the gold standard of prostate interventions for people who require a procedure. This involves removing (part of) the prostate by inserting a ...
Urology. [ edit on Wikidata] A prostatic stent is a stent used to keep open the male urethra and allow the passing of urine in cases of prostatic obstruction and lower urinary tract symptoms (LUTS). Prostatic obstruction [ 1] is a common condition with a variety of causes. Benign prostatic hyperplasia (BPH) is the most common cause, [ 2] but ...
Aquablation therapy ( AquaBeam) is a surgical procedure for men with lower urinary tract symptoms resulting from benign prostatic hyperplasia (BPH). It is in the early stages of study. [ 1] It is not categorized as minimally invasive as general anesthesia is required. [ 2] The procedure was developed by PROCEPT BioRobotics and combines real ...
Around one third of men will develop urinary tract (outflow) symptoms, of which the principal underlying cause is benign prostatic hyperplasia. [25] Once symptoms arise, their progress is variable and unpredictable with about one third of patients improving, one third remaining stable and one third deteriorating. [citation needed]
By Sneha S K and Sriparna Roy. (Reuters) -Ascendis Pharma said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult patients with a hormone disorder, sending the ...